Search clinical trials for: PD-1 checkpoint inhibitor

Total 106540 results

Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC

Lung Diseases | Neoplasms by Site | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Respiratory Tract Disease | Neoplasm, Bronchial

China
Wuxi People's Hospital

Recruiting

Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours

Cancer | PD-L1 Gene Mutation

China
Merck Sharp & Dohme LLC

Terminated

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

Advanced/Metastatic Melanoma

United States, Australia, Chile, France, Germany, Israel, Italy, Korea, Republic of, Norway, South Africa, Spain
Li Xiao Wei

Not yet recruiting

HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL) (HAI-TL)

Hepatocellular Carcinoma With PVTT

China
Mayo Clinic

Recruiting

NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis

Thumb Osteoarthritis

United States
Beijing YouAn Hospital
Beijing Gene Key Life Technology Co., Ltd.

Recruiting

Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy

Hepatocellular Carcinoma

China
Fujian Cancer Hospital

Not yet recruiting

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

Rectal Cancer
University of Pennsylvania

Recruiting

SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial (SAK)

Heart Failure With Preserved Ejection Fraction

United States
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital...

Active, not recruiting

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

Breast Cancer | Neoadjuvant Chemotherapy

China
Icahn School of Medicine at Mount Sinai
National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center; City...

Completed

Systematic Light Exposure for Fatigue in Breast Cancer Patients

Fatigue | Circadian Rhythm Disorders | Cancer-related Problem/Condition

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects

Advanced Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Solid Tumor

China
Otsuka Pharmaceutical Co., Ltd.

Completed

Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male Adults

Healthy Male Adults

Japan
Guangxi Medical University

Unknown

Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer

Advanced Liver Cancer

China
Duke University

Completed

Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia

Schizophrenia | Cigarette Smoking

United States
University Health Network, Toronto
University of British Columbia; McGill University; Centre for Addiction and Mental... and other collaborators

Completed

Canadian Biomarker Integration Network for Depression Study (CAN-BIND-1)

Major Depressive Disorder

Canada
Janssen Research & Development, LLC

Completed

Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone

Immunoassay | Antipsychotic

Belgium
Charite University, Berlin, Germany
University Hospital Muenster; Ruhr University of Bochum; University of Ulm

Completed

Apathy Cure Through Bupropion in Huntington's Disease (Action-HD)

Huntington's Disease | Apathy

Germany
University of Sao Paulo

Unknown

Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients (ARIQUELI)

Bipolar I Disorder

Brazil
Peking University
Ministry of Science and Technology of the People´s Republic of China

Unknown

Standard Comprehensive Intervention to Treat First-episode Schizophrenia

Schizophrenia

China
Eli Lilly and Company

Completed

Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia

Schizophrenia

United States
Pennsylvania College of Optometry

Completed

A Randomized Trial of Base-in Prism Reading Glasses Convergence Insufficiency in Children

Convergence Insufficiency

United States
University of Chicago

Withdrawn

A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy

Head and Neck Cancer

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

Carcinoma, Squamous Cell

Ukraine, United States, Argentina, Australia, Brazil, Canada, Chile, Colombia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Mexico, New Zealand, Norway, Poland, Portugal, Romania, Russian Federation, Spain, United Kingdom
Thomas Marron

Recruiting

Dupilumab_Metastatic NSCLC

Metastatic Non-small Cell Lung Cancer

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

Carcinoma, Renal Cell

Spain, United States, Australia, Canada, Chile, Colombia, France, Hungary, Israel, Korea, Republic of, Netherlands, New Zealand, Poland, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B)

Carcinoma, Renal Cell

United States, Australia, Canada, Chile, France, Hungary, Israel, Korea, Republic of, Netherlands, New Zealand, Poland, Spain, United Kingdom
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Carcinoma, Hepatocellular

Colombia, Israel, Taiwan, United States, Australia, Brazil, Chile, China, Denmark, France, Germany, Hong Kong, Hungary, Ireland, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Norway, Portugal, Puerto Rico, Spain, Thailand, Turke... and more
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)

Non-small Cell Lung Cancer

United States, Korea, Republic of, Ukraine
Curis, Inc.

Completed

A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas

Advanced Solid Tumors or Lymphomas

United States, Spain, Korea, Republic of, United Kingdom
Dana-Farber Cancer Institute
Partner Therapeutics (PTx)

Withdrawn

Sargramostim (GM-CSF) + PD-1

Metastatic Melanoma | Unresectable Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
Merck Sharp & Dohme LLC
Novartis Pharmaceuticals

Completed

A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)

Melanoma | Solid Tumors
John Kirkwood
Bristol-Myers Squibb; Secura Bio, Inc.

Recruiting

Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma

Unresectable Melanoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Completed

Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

United States
Canadian Cancer Trials Group
Melanoma and Skin Cancer Trials Limited

Recruiting

Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)

Unresectable/Metastatic Melanoma

Canada, Australia
Tianjin Medical University Cancer Institute and...

Recruiting

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

Early Stage Non-small Cell Lung Cancer

China
Merck Sharp & Dohme LLC

Completed

Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)

Metastatic Triple Negative Breast Cancer
Peking Union Medical College Hospital

Recruiting

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma | PD-1 Inhibitor | Regorafenib

China
University Hospital, Bordeaux

Recruiting

Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors (SPICI)

Metastatic Renal Cell Carcinoma | Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score

France
Yongchang Zhang

Recruiting

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

HER2 Insertion Mutation Positive Advanced NSCLC

China
Novartis Pharmaceuticals

Active, not recruiting

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Advanced Solid Tumors | Triple Negative Breast Cancer | Chordoma and Alveolar Soft Part Sarcoma

United States, Taiwan, Spain, Canada, Singapore, Italy, Japan, Israel, France
Genentech, Inc.

Completed

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Malignant Melanoma

United States
Second Affiliated Hospital, School of Medicine,...
Zhejiang Cancer Hospital; Sun Yat-sen University; Ningbo Medical Center Lihuili... and other collaborators

Recruiting

Multi-center Observational Study on the Progression of Atherosclerotic Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up

Plaque, Atherosclerotic | Programmed Cell Death Protein 1 Inhibitor

China
Third Affiliated Hospital, Sun Yat-Sen University

Recruiting

TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC

Hepatocellular Carcinoma

China
Merck Sharp & Dohme LLC

Completed

Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) (KEYNOTE-C11)

Classical Hodgkin Lymphoma

Poland, United States, Australia, Canada, Chile, France, Israel, Italy, Russian Federation, Spain, Turkey
NYU Langone Health
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer (SCLC)

United States
Tongji Hospital
Wuhan University; Sun Yat-sen University; Wuhan Union Hospital, China

Suspended

Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Merck Sharp & Dohme LLC

Completed

First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)

Esophageal Neoplasms

Taiwan, China, United States, Argentina, Australia, Brazil, Canada, Chile, Colombia, Costa Rica, Denmark, France, Germany, Guatemala, Hong Kong, Japan, Korea, Republic of, Malaysia, Peru, Romania, Russian Federation, South Africa, S... and more
Merck Sharp & Dohme LLC

Terminated

Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)

Neoplasms | Head and Neck Neoplasms | Colorectal Neoplasms

Australia, Hong Kong
Women's Hospital School Of Medicine Zhejiang University
Akeso

Not yet recruiting

Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors

Cervical Cancer | Uterine Cervical Neoplasms | Cancer of Cervix | Uterine Cervical Cancer | Cervical Neoplasms | Cancer of the Uterine Cervix

Search clinical trials for: PD-1 checkpoint inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations